Movement Alert｜PHARMARON Intraday Rise 3.29% in Regular Trading, New Overseas Fund Commitment Adds Event Support

Market Focus11-09

On November 9, PHARMARON recorded an Intraday Rise of 3.29% in Regular Trading, trading at HK$30.04 with turnover of HK$44.31 million.

A fresh event catalyst emerged after the company disclosed that its wholly owned subsidiary Pharmaron UK Limited committed US$10 million as a limited partner in HJ Double Helix Fund L.P., aiming to leverage specialized biopharma investment and research capabilities.

The latest disclosure stated that the subscription documents were signed on November 6. The move follows a solid operating update released in late October, when the company reported revenue of RMB12.003 billion for the first three quarters, up 19.01% year over year, while new orders rose by more than 30% and CDMO new orders increased by more than 40%. Recent broker commentary also turned constructive on the China CDMO space, providing additional background support for sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment